CBDM.T®, The Market and Business Intelligence Company Reviews The Biomanufacturing Market Sep 15, 2008
Key players: Amgen, Wyeth, GSK, Genentech, Novo Nordisk, Intermune, Ligand, Baxter, Genzyme, Biogen, DSM, Diosynth, Lonza Biologics, Merck Serono, Boehringer Ingelheim, Celltrion, Cora Biomanufacturing, Xcellerex, Avecia, Mera Pharmaceuticals, GTC Biotherapeutics, Pharming, Eden Biodesign, Genopole Biomanufacturing Center, Algenics. If you need market and business intelligence service in the biomanufacturing market, please contact us at contact@cbdmt. (Yahoo News -- Press Releases)
GTC Biotherapeutics fighting to keep Nasdaq Global listing Jul 22, 2008
Members: Not Registered. for free extra services. (Boston Business Journal, MA)
Mass. gas prices stabilize after 10 weeks of gains Jun 24, 2008
stock rises on collaboration GTC Biotherapeutics Inc., of Framingham, and Ovation Pharmaceuticals Inc. said they have entered into a collaboration agreement to develop and market ATryn in the United States. ATryn is GTC's recombinant form of a plasma protein with anticoagulant and anti-inflammatory properties. (Boston Globe)
The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline Jun 4, 2008
In the report covering Q4 2007, the top five of the most promising drugs launched or receiving approval were: DRUG DISEASE COMPANY ATryn(R) Hereditary antithrombin GTC Biotherapeutics/ deficiency LEO Pharma OncoVAX(R) Colon cancer, melanoma, Vaccinogen renal cell carcinoma Ixempra(TM) Breast cancer Bristol-Myers Squibb Isentress(TM) HIV-1 infection Merck Perforomist(TM) Chronic obstructive Dey Inhalation Solution pulmonary disease More analysis, as well as information on drugs entering clinical... (PR Newswire)
Cadle Co. to hire debt collectors for Mass. jobs Dec 11, 2007
seeks 'orphan drug' status Framingham's GTC Biotherapeutics Inc. said its drug candidate aimed at treating a rare blood-clotting disorder will get seven years of market exclusivity if approved in the United States. The Food and Drug Administration granted the drug candidate, called ATryn, "orphan drug" status. (Boston Globe)
Penn Veterinary Medicine report new strategy to create genetically modified animals Sep 21, 2007
The research was performed as a collaboration between Dobrinski, Ali Honaramooz, Susan Megee, Jinping Luo, Hannah Galantino-Homer, Mark Modelski, Fangping Chen and Wenxian Zeng of the Center for Animal Transgenesis and Germ Cell Research at the New Bolton Center of the Penn School of Veterinary Medicine; Fang Yang and P. Jeremy Yang of the Department of Animal Biology at Penn Veterinary Medicine; Margret Destrempes, Stephen Blash, David Melican, William Gavin, Yann Echelard and Susan Overton of... (EurekAlert!)
GTC Biotherapeutics gets FDA fast-track for ATryn Sep 5, 2007
THE REGION GTC Biotherapeutics Inc. has won fast-track designation from the Food and Drug Administratrion for ATryn, a protein produced in the milk of goats that has anticoagulant and anti-inflammatory properties. The Framingham company said fast-track designation allows for an accelerated review of ATryn as a treatment for patients with hereditary antithrombin deficiency who are at risk of developing deep vein thrombosis or thromboembolism while undergoing surgery or giving birth. (Boston Globe)
ThinkEquity Partners to Host G5: Fifth Annual Growth Conference Aug 27, 2007
com, Inc. UBET GREENTECH / EMERGING GROWTH Altair Nanotechnologies, Inc. ALTI Ascent Solar Technologies, Inc. ASTI Ceradyne, Inc. CRDN Clean Energy Fuels Corp. CLNE Comverge, Inc. COMV Electronic Recyclers (Private Company) EnerNOC, Inc. ENOC Fuel Tech Inc. FTEK FuelCell Energy, Inc. FCEL Harris & Harris Group, Inc. TINY Landec Corp. LNDC Luna Innovations Inc. LUNA Molecular Imprints (Private Company) NanoGram (Private Company) Nanophase Technologies Corporation NANX Nanosys (Private Company)... (TMC Net, CT)
Geoffrey F. Cox Mar 6, 2007
GTC Biotherapeutics narrows loss - Boston Business Journal ... GTC Biotherapeutics narrows loss. (Boston Business Journal, MA)
Nabi Biopharmaceuticals Announces Resignation of Thomas McLain as CEO and Appointment of Leslie Hudson as Interim CEO Feb 16, 2007
He has been chairman, president and chief executive officer of GTC Biotherapeutics, Inc., a biopharmaceutical company, since 2001. From 1997 to 2001, Cox was chairman of the board and chief executive officer of Aronex Pharmaceuticals, Inc., a biotechnology company. (PR Newswire)
Pharm Animals Crank Out Drugs Feb 16, 2007
With its tranquil ponds and rolling fields, the GTC Biotherapeutics farm in Charlton, Massachusetts, looks like a typical pastoral retreat. But its 1,400 goats don't produce any butter or cheese. (Wired News)
